2seventy bio Inc (TSVT)

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

BioSpace

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

BioSpace

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

BioSpace

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

BioSpace

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

BioSpace

2seventy bio executive sells shares worth $73 - Investing.com ZA - Investing.com South Africa

Investing.com South Africa

2seventy bio executive sells shares worth $73 By Investing.com - Investing.com

Investing.com

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

Zacks Investment Research

Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff - BioSpace

BioSpace

Q2 2024 EPS Estimates for 2seventy bio, Inc. Increased by Wedbush (NASDAQ:TSVT) - MarketBeat

MarketBeat

2seventy bio (NASDAQ:TSVT) Price Target Cut to $11.00 - Defense World

Defense World

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term - Simply Wall St

Simply Wall St

Earnings call: 2seventy bio eyes growth with focus on Abecma in Q1 2024 - Investing.com South Africa

Investing.com South Africa

Canaccord Genuity Group Cuts 2seventy bio (NASDAQ:TSVT) Price Target to $11.00 - MarketBeat

MarketBeat

Earnings call: 2seventy bio eyes growth with focus on Abecma in Q1 2024 - Investing.com Canada

Investing.com Canada

2seventy bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research

Zacks Investment Research

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress - 08.05.2024 - wallstreet:online

wallstreet:online

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress - Business Wire

Business Wire

2Seventy Bio earnings missed by $0.26, revenue fell short of estimates - Investing.com South Africa

Investing.com South Africa

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

2seventy bio (TSVT) to Release Earnings on Wednesday - MarketBeat

MarketBeat

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 - Business Wire

Business Wire

For 2seventy bio Insiders, Selling US$769k Of Shares Was A Smart Move - Simply Wall St

Simply Wall St

Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales

Zacks Investment Research

2seventy bio, Inc. (NASDAQ:TSVT) Receives $13.17 Consensus Price Target from Analysts - MarketBeat

MarketBeat

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nasdaq

Nasdaq

2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by SG Americas Securities LLC - Defense World

Defense World

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

Zacks Investment Research

2seventy bio, Inc. (NASDAQ:TSVT) Short Interest Up 29.7% in March - Defense World

Defense World

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

Zacks Investment Research

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros ... - Yahoo Finance

Yahoo Finance

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma

Zacks Investment Research

FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma

Zacks Investment Research

Citi raises 2Seventy Bio stock target on FDA approval - Investing.com

Investing.com

Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma - Seeking Alpha

Seeking Alpha

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround (NASDAQ:TSVT) - Seeking Alpha

Seeking Alpha

2seventy bio Finalizes Asset Sale and Executive Transition - TipRanks.com - TipRanks

TipRanks

2seventy bio focuses solely on Abecma post Regeneron deal - Investing.com

Investing.com

Casdin Capital buys $3.9m in 2seventy bio shares, sells swaps - Investing.com

Investing.com

Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion

Zacks Investment Research

Pi Health raises $30M; Gamida CSO hired at GRObio; 2seventy bio's drug label expansion - The Business Journals

The Business Journals

2seventy bio Appoints Eli Casdin and Charles Newton to Board of Directors - citybiz

citybiz

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion

Zacks Investment Research

Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Is 2seventy bio Stock Trading Higher On Monday? - Legend Biotech (NASDAQ:LEGN), Johnson & Johnson (NY - Benzinga

Benzinga